Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-320a mimic is a synthetic, double-stranded RNA oligonucleotide designed to mimic the biological activity of the endogenous tumor-suppressive microRNA, miR-320a. In various malignancies, including endometrial carcinoma, miR-320a expression is frequently downregulated, contributing to tumor progression. The mimic functions by binding to the 3' untranslated region (UTR) of specific target mRNAs, most notably the Insulin-like growth factor 1 receptor (IGF-1R). This binding leads to the degradation of the target mRNA or the inhibition of its translation, thereby suppressing the activation of downstream oncogenic pathways such as PI3K/AKT and mTOR. Preclinical studies indicate that restoration of miR-320a levels via mimics can induce G2/M phase cell cycle arrest and promote apoptosis, suggesting its potential as a therapeutic agent in gene therapy for cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microRNA-320a mimic.